Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque

Vista sencilla de ítem
dc.creatorRodríguez-Lago, Iago
dc.creatorRamírez de la Piscina, Patricia
dc.creatorElorza, Ainara
dc.creatorMerino, Olga
dc.creatorOrtiz de Zárate, Jone
dc.creatorCabriada, José Luis
dc.date.accessioned2020-08-25T20:58:48Z
dc.date.available2020-08-25T20:58:48Z
dc.date.created2020-08
dc.description.abstractenglishSince the first description of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infection produced by this microorganism (COVID-19) has been confirmed in 1,469,544 individuals around the world (www.healthmap.org/covid-19/). In Spain, the first case of COVID-19 was reported on the January 31, 2020, and currently there are 146,690 confirmed cases and 14,555 deaths secondary to this infection (Ministry of Health, Consumer Affairs and Social Welfare, April 7, 2020). In the Basque Country (Spain), 9452 subjects have a positive test for SARS-CoV-2 (April 7, 2020). Patients with inflammatory bowel disease (IBD) are of special interest during this outbreak because of the high proportion of them taking immunomodulators or biologics. There is also a possible increased risk of viral infections, especially in those receiving thiopurines.1,2 Our aim was to describe the characteristics of patients with IBD with a positive test for SARS-CoV-2, including the course of the infection in terms of medical therapy, hospital or intensive care unit (ICU) admission, and death.spa
dc.format.extent3 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1053/j.gastro.2020.04.043spa
dc.identifier.issn0016-5085spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S0016508520305606spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/12260
dc.language.isoengspa
dc.publisherGastroenterologyspa
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccessspa
dc.rights.localAcceso restringidospa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subject.keywordImmunosuppressionspa
dc.subject.keywordInflammatory Bowel Diseasespa
dc.subject.keywordSARS-CoV-2spa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleCharacteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basquespa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
Characteristics-and-Prognosis-of-Patients-With-Inflammatory-Bow_2020_Gastroe.pdf
Tamaño:
140.3 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS